Introduction to Randomized Discontinuation

Discover more insights into Randomized Discontinuation

Keywords frequently search together with Randomized Discontinuation

Narrow sentence examples with built-in keyword filters

More Randomized Discontinuation sentence examples

10.1016/j.cllc.2018.10.006

Introduction: Cabozantinib, an orally bioavailable tyrosine kinase inhibitor with activity against MET, vascular endothelial growth factor receptor 2, AXL, ROS1, and RET was assessed in patients with non–small‐cell lung carcinoma (NSCLC) as part of a phase II randomized discontinuation trial with cohorts from 9 tumor types.

Full Text

Learn more from Randomized Discontinuation

Keywords related to Randomized

Randomized Observational Randomized Kaczmarz Randomized Dietary Randomized Multiple Randomized Lifestyle Randomized Investigation Randomized Dose Response Randomized Evaluation Randomized Multicenter Randomized Efficacy Randomized Multicentric Randomized Response Randomized Observer Blind Randomized Designs Randomized Controlled Randomized Preference Randomized Waitlist Randomized Impress Randomized Type Randomized Smoking Randomized Single Blinded Randomized Tandem Randomized Cross Randomized Split Randomized Placebo Randomized Training Randomized Group Randomized Prospective Randomized Treatment Randomized Triple Blind Randomized Hybrid Randomized Encodings Randomized Measurements Randomized Multi Center Randomized Block Randomized Controlled Trial Randomized Crossover Randomized Algorithm Randomized Vehicle Controlled Randomized Cluster Randomized Trees Randomized Vaccine Randomized Prime Randomized Quality Randomized Parallel Group Randomized Parallel Controlled Randomized Cross Over Randomized Active Controlled Randomized Interventional Randomized Implementation Explore More

Keywords related to Discontinuation

Randomized Discontinuation

Encyclopedia

Jul 04, 2022

What is/are Randomized Discontinuation?

Randomized Discontinuation - Introduction: Cabozantinib, an orally bioavailable tyrosine kinase inhibitor with activity against MET, vascular endothelial growth factor receptor 2, AXL, ROS1, and RET was assessed in patients with non–small‐cell lung carcinoma (NSCLC) as part of a phase II randomized discontinuation trial with cohorts from 9 tumor types. ^[1]